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For patients with stage III non-small-cell lung cancer with unresectable or inoperable
tumors, deﬁnitive chemoradiotherapy is often utilized. Historically, local control and overall
survival rates have been poor. In an effort to improve local control, new chemotherapeutic
agents in combinationwith higher doses of radiotherapy have been investigated. Early dose
escalation trials date back to the 1980s, and the feasibility and efﬁcacy of dose escalation for
patients with inoperable stage III lung cancer continue to be topics of investigation. Herein,
we review the evolution of chemotherapy as it relates to treatment of unresectable stage
III lung cancer, and we outline the early and the more recent dose escalation studies.While
dose escalation appears to provide a modest beneﬁt in terms of preventing local failure
and improving overall survival, advances in diagnostic imaging and radiotherapy treatment
have possibly resulted in selection of a more favorable patient population. These variables
make statements regarding the beneﬁt of dose escalation challenging.
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INTRODUCTION
Lung cancer is the most common type of cancer worldwide and is
the leading cause of death due to cancer (American Cancer Soci-
ety, 2007). An estimated 1.5 million new cases were expected in
2007, and 975,000 men and 376,000 women were projected to die
of their disease. The incidence of lung cancer is highest in North
America, Eastern Europe, and China. Surgery, and more recently
stereotactic body radiotherapy, is the standard of care for patients
with non-small-cell lung cancer (NSCLC) operable AJCC stage
I–III patients. Unfortunately, 30–40% of patients present with
locally advanced stage III and IV disease, and overall survival rates
for this cohort of patients ranges from 1 to 2 year. For patients
with Stage III or IV NSCLC who have unresectable or inopera-
ble tumors, deﬁnitive chemoradiotherapy is typically utilized. The
timing of chemotherapy and radiotherapy (chemo-RT), and opti-
mal chemotherapeutic agents and radiation dose have been the
focus of numerous clinical trials. Historically, aminimumof 60Gy
has been considered standard for deﬁnitive treatmentdue to results
from the landmark clinical trial, RTOG 73-01. In this study, 378
patientswith inoperable or unresectable stage IIINSCLCwere ran-
domized to receive a dose of 40Gy split-course or radiotherapy to
40, 50, or 60-Gy in a continuous course at 2Gy per fraction. Rates
of local failure correlated with radiation doses, with an improve-
ment seen with dose escalation: 52% with 40Gy, 41% with 50Gy,
and 30% with 60Gy (Perez et al., 1982). While 60Gy proved to
be more effective than 40Gy in preventing a local failure, rates
remained high. Le Chevalier et al. used chest x-ray imaging as well
as visual inspection and histologic examination using ﬁberoptic
bronchoscopy to evaluate response to chemo-RT in patients with
NSCLC. Local control rates were poor, in the range of 15–17% at
1 year (Le Chevalier et al., 1991). A metaanlysis by Auperin et al.
(2010) reported an increase in OS in patients receiving concurrent
chemo-RT, and this was attributed to an increase in locoregional
control. Local control in patients with lung cancer remains difﬁ-
cult to assess, and often the absence of disease progression is used
to identify a successful treatment regimen.
For many decades, radiotherapy to 60Gy was the standard of
care. More recently, several studies have addressed the safety and
efﬁcacy of treating patients with NSCLC with higher doses of
radiation therapy. Herein, we hope to summarize the early dose
escalation studies forNSCLC and to describe the recent Phase I–III
studies which have addressed this topic.
CHEMOTHERAPY
INDUCTION CHEMOTHERAPY
It is difﬁcult to discuss radiotherapy for unresectable/inoperable
Stage III lung cancer without describing the role of induction or
concurrent chemotherapy. As previously mentioned, RTOG 73-
01 established radiotherapy as the standard of care for treatment
of locally advanced NSCLC. Radiotherapy alone remained the
standard of care until the CALGB published their results using
induction chemotherapy (CALGB 84-33). This randomized trial
was designed to evaluate the beneﬁt of adding induction cisplatin
(100mg/m2 on days 1 and 29) and vinblastine (5mg/m2 on days 1,
8, 15, 22, and 29) chemotherapy to the standard radiotherapy reg-
imen of 60Gy in 30 fractions. A total of 78 patients were enrolled
on the chemo-RT arm and 77 on the RT alone arm.After 7 years of
follow-up, themedian survival was greater in the chemo-RT group
(13.7months) than in theRT alone group (9.6months; p = 0.012).
The 5-year survival for these patients was 17 and 6% respectively
(Dillman et al., 1996).
RTOG 88-08 was initiated to conﬁrm the results of CALGB
84-33 and to test the efﬁcacy of hyperfractionated radiotherapy.
This was a three arm trial in which 462 patients were randomized
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to 2months of induction cisplatin (100mg/m2) and vinblastine
(5mg/m2) followed by 60Gy of radiation delivered at 2Gy per
fraction or to 60Gy of radiotherapy alone delivered at 2Gy per
fraction or to 69.6Gy of radiotherapy alone given at 1.2 Gy per
fraction BID. Patients were enrolled between 1989 and 1992 and
followed for 5 years. Patients who received induction chemother-
apy had an improvement in 5-year overall survival compared to
patients who received RT alone (8% for chemo-RT, 5% for stan-
dardRT,6% forhyperfractionatedRT; Sause et al., 2000). LeCheva-
lier et al. randomized 353 patients to induction chemotherapy
including vindesine (1.5mg/m2 on days 1 and 2), cyclophos-
phamide (200mg/m2 on days 2–4), cisplatin (100mg/m2 on day
2), and lomustine (50mg/m2 on day 2 and 25mg/m2 on day 3)
followed by radiation to 65Gy or to radiotherapy alone. The 3-
year survival rates were 4% in the RT alone group and 12% in the
chemo-RT arm (p< 0.02). As previously mentioned, 2 year rates
of local control were 17 and 15% respectively (Le Chevalier et al.,
1991) (Table 1). A meta-analysis by Pritchard andAnthony (1996)
found that the relative risk of death with the addition of sequen-
tial chemotherapy to radiotherapy was 0.86, 0.85, and 0.80 at 1, 2,
and 3 years respectively. While these studies conﬁrmed the beneﬁt
of adding induction chemotherapy to radiotherapy, local control,
and overall survival rates remained poor.
SEQUENTIAL VS. CONCURRENT CHEMOTHERAPY
Three large phase III trials evaluated the efﬁcacy of sequential
vs. concurrent chemotherapy (Table 2). Furuse et al. random-
ized 320 patients to two cycles of mitomycin (8mg/m2), vindesine
(3mg/m2), and cisplatin (80mg/m2; MVP) chemotherapy given
every 28 days with a concurrent split-course of RT to 56Gy or to
two cycles of MVP followed by a continuous course of RT to 56Gy.
The median survival was 16.5months for the concurrent arm and
13.3months for the sequential chemo-RT arm (p = 0.04), and the
5-year survival was 15.8 vs. 8.9% respectively (p = 0.0001). Local
control rates were 50% on the concurrent arm and 35% on the
sequential arm (p = 0.07; Furuse et al., 1999).
RTOG 9410 was a three arm randomized trial for patients with
unresectable Stage II–III NSCLC. A total of 595 patients were
randomized to sequential chemo-RT with cisplatin (100mg/m2)
and vinblastine (5mg/m2) followed by RT to 60Gy (similar to
Table 1 | Randomized phase III studies of induction chemotherapy for unresectable, locally advanced NSCLC.
Reference Trial Number of
patients
Induction
chemotherapy
Radiation dose
(Gy)/# fractions
Median survival
(months)
Dillman et al. (1996) CALGB 84-33 155 C-vinblastine 60/30 13.7
– 60/30 9.6
Sause et al. (2000) RTOG 88-08 462 C-vinblastine 60/30 13.2
– 60/30 11.4
– 69.6/58 12
Le Chevalier et al. (1991) – 353 VCPC 65/26 12
– 65/26 10
C-vinblastine, cisplatin and vinblastine; VCPC, vindesine, lomustine, cisplatin, and cyclophosphamide.
Table 2 | Select studies comparing induction, concurrent, and consolidation chemotherapy for unresectable, locally advanced III NSCLC.
Reference Trial Number of patients Chemotherapy Radiation dose
(Gy)/# of fractions
Median survival
(months)
Induction Concurrent Consolidation
Furuse et al. (1999) – 320 CMV – – 56/28 13.3
– CMV – 56/28 16.5
Fournel et al. (2005) – 205 C-vinorelbine – – 66 14.5
– CE C-vinorelbine 66 16.3
Curran et al. (2003) RTOG 9410 595 C-vinblastine – – 60/30 14.6
– C-vinblastine – 60/30 17
– CE – 69.6/58 15.2
Vokes et al. (2007) CALGB 9431 366 CaT CaT – 66/33 14
CaT – 66/33 12
Belani et al. (2005) LAMP 257 CaT – – 63/34 12
CaT CaT – 63/34 12.8
– CaT CaT 63/34 16.1
CMV, cisplatin, mitomycin, and vindesine; C-Vinorelbine, cisplatin and vinorelbine; C-vinblastine, cisplatin and vinblastine; CE, cisplatin and etoposide; CaT, carboplatin
and paclitaxel.
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the CALBG 8433 induction chemotherapy arm) or to concurrent
chemo-RT utilizing the same chemo and RT dose or to concurrent
chemo-RT with cisplatin (50mg/m2) and etoposide (50mg BID)
with RT to 69.6Gy in 1.2Gy fractions given BID. The median
survival rates were 14.6months (sequential arm), 17.0months
(concurrent arm), and 15.2months (concurrent BID arm). The
concurrent chemo-RT arm had a better 4-year overall survival
than the sequential arm (21 vs. 12%, p = 0.046). The locoregional
failure rates were 50% (sequential arm), 43% (concurrent QD
arm), and 34% (concurrent BID arm). The BID RT arm had a
higher rate of acute toxicity, but there was no difference in late
toxicity among the groups (Curran et al., 2003).
Fournel et al. published a third trial comparing sequential vs.
concurrent chemoradiotherapy, and they also tested the utility of
consolidation chemotherapy. Patients were randomized to receive
either two cycles of induction cisplatin (120mg/m2) and vinorel-
bine (30mg/m2) followed by 66Gy or to two cycles of concurrent
cisplatin (20mg/m2) and etoposide (50mg/m2) with RT to 66Gy
followed by two cycles of consolidation cisplatin (80mg/m2) and
vinorelbine (30mg/m2). Local control was higher in the concur-
rent arm (40 vs. 24%). The 2- and 4-year overall survival rates
trended toward improvement in the concurrent arm (were 26.5
and 14.2%, respectively, in the sequential arm and 39.3 and 20.7%,
respectively) however were not statistically different. The median
survival rates (14.5months for the sequential arm,16.3months for
the concurrent arm, p = 0.24) were similar to those published by
Furuse et al. (1999) and the overall survival rates were comparable
to those from RTOG 94-10 (Fournel et al., 2005).
These three phase III clinical trials established concurrent
chemo-RT as the standard of care for patients with unre-
sectable/inoperable Stage III lung cancer. This is supported by
work by Schaake-Koning et al. who compared radiotherapy with
cisplatin given either daily (6mg/m2) or weekly (30mg/m2) to
treatment with radiotherapy alone. Radiation was given in a split-
course fashion to a total of 55Gy. There was an improvement
in survival with daily cisplatin chemoradiotherapy compared to
radiotherapy alone (p = 0.009). There was no signiﬁcant differ-
ence in survival when the weekly cisplatin group was compared
with the radiotherapy alone group. There was an improvement in
progression free survival in those treated with cisplatin yet no dif-
ference in distant metastases suggesting that obtainment of local
control can lead tohigher rates of overall survival (Schaake-Koning
et al., 1992).
A metaanlysis by Auperin et al. compiled data from six
trials (CALGB 8831, WJLCG, RTOG 9410, GMMA Ankara,
GLOT_GFPC NPC 95-01, EORTC 08972) including 1205 patients
to evaluate the beneﬁt of concomitant vs. sequential chemora-
diotherapy. Concomitant chemo-RT was associated with a 4.5%
absolute survival beneﬁt at 5 years. There was an improvement in
locoregional progression free survival (6% at 5 years, HR 0.777)
but no difference in the rate of distant metastases (40%,HR 1.04),
thereby highlighting the importance of local control in promoting
survival (Auperin et al., 2010).
More recently, cisplatin chemotherapy has been replaced by
regimens which are believed to more effective and less toxic based
on Phase II studies. CALGB 39801, a phase III study, random-
ized 366 patients to two cycles of induction chemotherapy with
paclitaxel (200mg/m2) and carboplatin (AUC= 6) every 3weeks
followed by paclitaxel (50mg/m2) and carboplatin (AUC= 2)
with RT to 66Gy or to the same treatment without induc-
tion chemotherapy. Unfortunately, the median survival was only
12months without induction chemotherapy and 14months with
induction chemotherapy (p = 0.3; Vokes et al., 2007). Regardless,
manyof themore recent studies includingRTOG0117 andCALGB
30105 have utilized carboplatin and paclitaxel based regimens and
have shown promising results.
CONSOLIDATION CHEMOTHERAPY
Use of consolidation chemotherapy has been studied in several
randomized phase III trial including the trial by Fournel et al.
(2005) as mentioned above. The locally advanced multimodality
protocol (LAMP) trial was a phase II, three arm study evaluat-
ing treatment with two cycles of induction carboplatin (AUC 6)
and paclitaxel (200mg/m2) followed by 63Gy RT or to two cycles
of the same chemotherapy followed by concurrent weekly carbo-
platin (AUC 2) and paclitaxel (45mg/m2) with RT to 63Gy or to
the same concurrent chemo-RT followed by consolidation carbo-
platin (AUC 6) and paclitaxel (200mg/m2). The median survival
times for the three arms were 13, 12.8, and 16.1months respec-
tively (Belani et al., 2005). SWOG conducted a trial (9019) using
concurrent cisplatin (50mg/m2), etoposide (50mg/m2), and radi-
ation therapy (45Gy). In the absence of metastatic disease,patients
received additional cisplatin and etoposide, and radiation therapy
was delivered to a total of 61Gy. This regimen resulted in a median
survival of 15months (Albain et al., 2002). They conducted a sim-
ilar trial, SWOG 9504, using docetaxel for consolidation, and the
median survival was 26months (Gandara et al., 2003). A phase III
study by theHoosierOncologyGroup (HOG) evaluated the effects
of consolidation with docetaxel and found no survival beneﬁt and
increased complication rates with docetaxel (Hanna et al., 2008).
DOSE ESCALATION IN THE THREE-DIMENSIONAL
CONFORMAL RADIOTHERAPY ERA
Despite the beneﬁt obtained by adding concurrent and consol-
idation chemotherapy to radiotherapy regimens, local control,
and overall survival rates remain poor. Escalation of radiother-
apy doses has been employed to improve overall survival by both
preventing local progression of disease and eliminating a source
for distant metastases. Dose escalation is possible due to improve-
ments in diagnostic imaging and radiotherapy techniques over
the past 40 years. In early RT studies such as RTOG 73-01, CALGB
8433, RTOG 88-08, and RTOG 9410, RT treatment plans were
based on plain ﬁlm imaging. Treatment ﬁelds were designed to
encompass gross tumor as well as elective nodes. Currently, radi-
ation oncologists may use PET–CT imaging to precisely deﬁne
tumor and involved nodal volumes and three dimensional confor-
mal radiotherapy (3D-CRT) and Intensity-modulated radiation
therapy (IMRT) to deliver radiotherapy.
POSITRON EMISSION TOMOGRAPHY
PET–CT imaging should be used whenever available for patients
who will undergo deﬁnitive RT for stage III NSCLC. It can be used
to identify patients with distant metastases (up to 20% of clinical
Stage III patients) and patients who have locally advanced dis-
ease not amenable to surgery (MacManus et al., 2001). PET–CT
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imaging can guide radiotherapy planning and allow for treatment
of only the primary and involved nodes. Usingmediastinoscopy or
thoracotomy to conﬁrm nodal involvement, Darling et al. (2011)
report that the sensitivity of PET imaging is 70%and the speciﬁcity
is 94%. In a meta-analysis by Toloza et al. (2003), the sensitivity
and speciﬁcity of mediastinal staging was 84 and 89%, respec-
tively, for PET imaging compared to 57 and 84%, respectively, for
CT imaging.
Bradley et al. (2005) evaluated radiotherapy treatment vol-
umes as contoured onCT imaging vs. volumes contoured PET–CT
imaging. Twenty-six patients with Stage I–III NSCLC underwent
sequential CT and FDG-PET simulation. PET imaging altered
treatment volumes in 14 (58%) patients; it was useful in distin-
guishing tumor from atelectasis in three cases leading to a decrease
in treatment volume, and 10 patients were found to have nodal
disease undetected on CT imaging alone, leading to an increase in
treatment volume. At the University of Michigan, 14 patients with
locally advanced NSCLC underwent PET–CT imaging midway
through a course of deﬁnitive radiotherapy. The mean decrease in
tumor volume as seen on mid-treatment PET–CT was 44%, and
this information was used to escalate the RT dose and to reduce
dose to normal tissue (Feng et al., 2009). The RTOG is planning a
phase II trial (RTOG 1106) of adaptive radiation using during-
treatment FDG-PET/CT to direct dose escalation for NSCLC.
While PET–CT imaging has allowed for more accurate staging
of patients with NSCLC, increased exclusion of high risk patients
with disease outside the thorax poses a challenge when attempting
to compare modern day randomized clinical trials to historical
trials of the past.
ELECTIVE LYMPH NODE IRRADIATION
Traditionally, before the widespread use of CT imaging, radiother-
apy treatment ﬁeldswere designed to encompass bilateral hilar and
mediastinal lymph nodes, regardless of their involvement. With
CT and PET–CT imaging, better assessment of the locoregional
nodal burden is feasible. In addition, several studies have shown
that omitting elective nodal irradiation (ENI) does not compro-
mise local control or overall survival. ENI irradiation makes dose
escalation difﬁcult due to the radiosensitivity of normal lung tis-
sue. In an effort to determine the necessity of ENI, Yuan et al.
randomized 200 patients to cisplatin-based chemoradiotherapy
with treatment of either elective nodes (RT 60–64Gy) or involved
node irradiation (68–74Gy). Patients in the involved ﬁeld armhad
a better overall response rate (90 vs. 79%,p = 0.032) and improved
6-year local control rate (51 vs. 36%, p = 0.032). There was a sig-
niﬁcant overall survival beneﬁt for elective node irradiation at
2 years (39.4 vs. 25.6%, p = 0.048) but not at 1 or 5 years. The
rate of radiation pneumonitis was lower in patients who received
involved ﬁeld radiation (17 vs. 29%, p = 0.044; Yuan et al., 2007).
Elective nodal failure occurred in 4% of patients in the ENI group
and 7% of the patients in the INI group (p = 0.352). The elective
nodal failure rate in patients treated without ENI ranges from 4 to
7% (Rosenzweig et al., 2001; Sulman et al., 2009).
THREE DIMENSIONAL CONFORMAL
RADIOTHERAPY/INTENSITY-MODULATED RADIOTHERAPY
Radiotherapy techniques have drastically changed over the past
several decades. Many of the trials evaluating chemo-RT for Stage
III lung cancer were performed in the era of two dimensional
radiotherapy. The advent of CT based planning in conjunction
with increasing sophistication of linear accelerators have allowed
for improvement in precision of 3D-CRT plans. 3D-CRT has
allowed for quantiﬁcation of dose to normal structures thereby
leading to standardization of dose constraint limits. This has
allowed for more ubiquitous treatment amongst radiation oncol-
ogy facilities. Intensity-modulated radiation therapy (IMRT) has
been studied as a potential mechanism for allowing dose esca-
lation. Lievens et al. (2011) performed a dose escalation plan-
ning study in which 3D and IMRT plans were created for 35
patients withNSCLC treated to 66Gy. IMRT resulted in signiﬁcant
decreases in mean lung and maximal spinal cord doses, how-
ever esophageal doses were increased. Four-dimensional imaging
with motion tracking and control, daily on-board imaging, and
adaptive radiotherapy are all areas of intense interest and research.
While these are enormous topics in and of themselves, sufﬁce it to
say that these technologies have, and will continue to allow us to
create more conformal radiotherapy plans while minimizing dose
to critical structures. As this is accomplished, dose escalation will
ideally lead to more effective treatment without excessive toxicity.
EARLY TRIALS OF DOSE ESCALATION
One of the earliest dose escalation trials for inopera-
ble/unresectable Stage III NSCLC was RTOG 8311, a phase I/II
trial of hyperfractionated RT. Patients were randomized to receive
60, 64.8, or 69.6Gy at 1.2 Gy per fraction. After an initial toxi-
city analysis revealed acceptable risks, patients were randomized
to 74.4 or 79.2Gy. In total, 848 patients were randomized, and
there was no signiﬁcant difference in acute or late toxicity, includ-
ing the risk of radiation pneumonitis. Patients who were treated
to at least 69.6Gy had a better median survival (13months) than
those treated to lower doses (Cox et al., 1990). There was no differ-
ence in survival amongst the ﬁve arms, however when the authors
included 350 patients from CALGB 84-33 who met the same
eligibility criteria, they found that treatment to 69.6Gy resulted
in a better median survival than those treated to with RT alone to
a lower total dose. From 1983 to 1989,Arriagada et al. randomized
353 patients to RT alone to 65Gy or to RT to 65Gy with neoadju-
vant and adjuvantVCPC (vindesine, cyclophosphamide, cisplatin,
lomustine) chemotherapy. The 2-year survival rate was 14% in the
RT alone group and 21% in the chemo-RT group (p = 0.08). The
local control rate at 1 year was 17 and 15%.While local control and
survival remained poor, these studies demonstrated that treatment
to 65Gy was feasible (Arriagada et al., 1991).
Based on the dose escalation trials of the 1970s and 1980s
including RTOG 73-01, RTOG 83-11, and the work by Arriagada
et al. (1991) the RTOG opened a radiation only, dose escalation
study, RTOG 93-11. Patients were randomized to one of four
radiotherapy doses (70.9, 77.4, 83.8, 90.3Gy, 2.1 Gy per fraction)
based on the lung V20 (volume of the lung that receives 20Gy).
There were two treatment related deaths in the 90.3Gy arm, and
therefore this was deemed too toxic. Radiation dose was safely
escalated to 83.8Gy for patients with a V20 <25% and to 77.4Gy
for patients with a V20 between 25 and 36% (Bradley et al., 2005).
The University of Michigan performed a dose escalation trial in
which they randomized 106 patients with NSCLC Stage I–III to
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63–103Gy in 2.1Gy per fraction. ENI was not performed and 3D-
CRT was used for treatment delivery. The majority of the patients
did not receive chemotherapy. Median survival was 19months,
and multivariate analysis revealed that radiation dose was a pre-
dictor of OS (p = 0.0006). The 5-year OS rate was 4, 22, and 28%
for patients receiving 63–69, 74–84, and 92–103Gy, respectively
(Kong et al., 2005).
RATIONALE FOR DOSE ESCALATION TO 74 Gy
The University of North Carolina has undertaken several stud-
ies to evaluate dose escalation and the role of chemotherapy. A
Phase I/II trial reported by Rosenman et al., 2002) reported on 62
patients with Stage III NSCLC treated with two cycles of induction
carboplatin (AUC 6) and paclitaxel (225mg/m2) followed by con-
current weekly carboplatin (AUC 2) paclitaxel (45mg/m2) with
radiation doses escalated from 60 to 74Gy. The median survival
was 24months, and 38% of patients were alive at 3 years. While
there was not an association between dose and overall survival,
the authors concluded that RT to 74Gy was safe and could pos-
sibly contribute to lengthening survival (Rosenman et al., 2002).
The University of North Carolina continued their dose escala-
tion work, and in 2004 Socinksi et al. reported on a phase I
dose escalation study to doses of 78, 82, 86, and 90Gy. Patients
received induction chemotherapy with carboplatin (AUC= 5),
irinotecan (100mg/m2), and paclitaxel (175mg/m2) followed by
weekly carboplatin (AUC= 2) and paclitaxel (45mg/m2) with
radiotherapy. RT dose was escalated without dose limiting toxicity,
and the median survival was 24months (Socinski et al., 2004). The
NCCTG performed a dose escalation study in which 15 patients
were treated with weekly carboplatin (AUC= 2) and paclitaxel
(50mg/m2) and dose escalated radiotherapy from 70 to 78Gy.
Two dose limiting toxicities occurred in the four patients treated
to 78Gy,and therefore themaximumtolerated dose, as reported by
Rosenman et al. was determined to be 74Gy. The median survival
was 37months (Schild et al., 2006).
As previously mentioned, it was established that concurrent
chemoradiotherapy was preferable to sequential chemotherapy
followed by radiotherapy or to radiotherapy alone, and there-
fore the RTOG initiated a phase I dose escalation study, RTOG
0117, to evaluate maximum tolerated radiation doses in the set-
ting of chemotherapy. A phase II component of this study was
designed to determine survivorship at 12months. The phase I
trial was designed to dose escalate with increasing dose per frac-
tion, beginning at 75.25Gy in 2.15Gy per fractionwith concurrent
weekly carboplatin (AUC 2mg/m2) and paclitaxel (50mg/m2).
Eight patients were treated to 75.25Gy, and 75% developed grade
≥3 toxicities. Due to these treatment related complications, the
dose was de-escalated, and themaximum tolerated dose was deter-
mined to be 74Gy (Bradley et al., 2010a). In the phase II portion
of the study, 55 patients received 74Gy, and the median follow-
up was 19.3months. The median survival was 25.9months, and
72.7% of patients were alive at 1 year. Twelve patients experienced
grade ≥3 lung toxicity (Bradley et al., 2010b).
The CALGB conducted a randomized phase II trail, CALGB
30105, to evaluate survival in patients with locoregionally
advanced NSCLC cancer treated with 74Gy of RT with induction
and concurrent chemotherapy. Forty-three patients were treated
with induction carboplatin (AUC= 6) and paclitaxel (225mg/m2)
on days 1 and 22 followed by weekly carboplatin (AUC= 2) and
paclitaxel (45mg/m2) with concurrent RT to 74Gy. Twenty-six
patients were treated with induction carboplatin (AUC 5, days 1
and 22) and gemcitabine (1000mg/m2, days 1, 8, 22, 29) followed
by concurrent weekly gemcitabine (35mg/m2) and radiother-
apy to 74Gy. The primary end point was survival at 18months.
The gemcitabine arm was closed early due to a higher than
expected rate of pulmonary toxicity. The median survival was
24.3months for the carboplatin/paclitaxel arm, which was longer
than expected, and 12.5months for the gemcitabine arm (Socinski
et al., 2008) (Table 3).
In addition to these prospective trials, retrospective studies have
supported the use of higher doses of radiation in deﬁnitive treat-
ment of locally advanced NSCLC. Wang et al. reported on 237
consecutive Stage III patients who were treated with RT alone
(n = 106), sequential chemotherapy followed by RT (n = 69), or to
concurrent chemotherapy and RT (n = 62). Median survival was
7.4, 14.9, and 15.8months respectively. Both radiation dose and
use of chemotherapy were predictors of overall survival (Wang
et al., 2008). Machtay et al. analyzed the biologically effective dose
of the radiotherapy treatment for 1356 patients treated on seven
RTOG trials (RTOG 88-08, 90-15, 91-06, 92-04, 93-09, 94-10, and
98-010). There was a correlation between BED and both overall
survival and local control. A 1-Gy BED increase was associated
with a 4% improvement in survival, and a 1-Gy tBED resulted in
a 3% improvement in locoregional control (Machtay et al., 2010).
These phase I/II trials and retrospective data have demon-
strated a small, but important, improvement in overall survival for
patients treated with concurrent chemotherapy and dose escalated
radiotherapy. RTOG 0617 is a randomized, phase III, prospective
clinical trial which was designed to conﬁrm or refute the beneﬁt
of dose escalated RT. This started as a two arm trial with ran-
domization to either concurrent weekly paclitaxel (45mg/m2) and
cisplatin (AUC= 2) with either 60 or 74Gy of radiation therapy at
2Gy per fraction followed by two cycles of consolidation paclitaxel
(200mg/m2) and cisplatin (AUC= 6). In 2008, the protocol was
modiﬁed, and cetuximabwas added to the randomization, thereby
making RTOG 0617 a four arm randomized trial. In June of 2011,
the high dose radiation arms (74Gy) were closed as an interim
analysis revealed that the high dose radiotherapy arm could no
longer show a survival beneﬁt even with further accrual. This
analysis did not identify particular safety concerns. The remaining
two arms of the study which randomize patients to cisplatin, pacli-
taxel, and RT to 60Gy with or without cetuximab are still open to
accrual.
Evaluating the local control and overall survival beneﬁt of dose
escalation for patients with Stage III NSCLC can be quite chal-
lenging. Over the past several decades, the use of chemotherapy
has increased, and resultantly patients who are unable to tolerate
aggressive chemotherapeutic regimens have not been eligible for
many of the recent Phase II and Phase III clinical trials. In addi-
tion, dose escalation is only made possible by the use of smaller
ﬁeld sizes and increased conformality of radiation therapy plans.
Strict dose constraints guide daily practice, and therefore patients
with large tumors are often excluded from trials because these
patients cannot be treated without exceeding radiotherapy dose
constraints. These factors lead to selection of patients with bet-
ter performance status, fewer medical comorbidities, and smaller
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Table 3 | Select trials of dose escalation for Stage III inoperable non-small-cell lung cancer.
Reference Trial Number of
Patients
Chemotherapy Radiation dose Outcomes
Perez et al. (1982) RTOG 73-01 378 – 40, 50, 60Gy Improvement in local control with
higher dose.
Cox et al. (1990) RTOG 8311 848 – <69.6Gy, >69.6Gy,
up to 79.2Gy
Improvement in median survival
(13months) for >69.6Gy.
Bradley et al. (2005) RTOG 93-11 176 – 70.9–90.3Gy 90.3Gy maximum tolerated dose.
Established safety of dose escala-
tion based on lung V20.
Kong et al. (2005) – 106 – 63–103Gy OS improved with increasing dose.
MTD not reached.
Rosenman et al. (2002) – 62 Induction and concurrent
CaT
60–74Gy 74Gy was safe in setting of concur-
rent chemotherapy.
Socinski et al. (2004) – 29 Induction CaIT. Concur-
rent CaT
78–90Gy MTD not reached.
Schild et al. (2006) – 15 Concurrent CaT 70–78Gy MTD 74Gy.
Bradley et al. (2010a) RTOG 0117,
Phase I
17 Concurrent CaT Started at 75.25Gy Signiﬁcant grade 3 toxicity at
75.25Gy. MTD determined to be
74Gy.
Socinski et al. (2008) CALGB
30105
69 Induction and concurrent
CaT v. induction CaGem
with concurrent Gem.
74Gy Closed early due to high toxi-
city with Gem. Median survival
24.3months (CaT) vs. 12.5months
(CaGem).
CaT, carboplatin and paclitaxel; CaIT, carboplatin, irinotecan, and paclitaxel; Gem, gemcitabine; CaGem, carboplatin and gemcitabine.
tumors for enrollment on our clinical trials. Ultimately this will
result in better outcomes than historical standards, however the
comparative groups are not necessarily equivalent.
TOXICITY ASSOCIATED WITH DOSE ESCALATION
Dose escalation for lung cancer does not come without costs in
terms of radiation induced damage to normal tissues. Lung and
esophageal toxicity can be morbid and lead to death. Lee et al.
published late toxicity data from the phase I/II dose escalation tri-
als completed at the University of North Carolina. Eighty-eight
patients who received ≥66Gy were included in the analysis. A
total of 28 late complications were identiﬁed in 21 patients. The
late complications were pulmonary (n = 8), esophageal (n = 6),
cardiac (n = 9), osseous (n = 6), and a second primary (n = 2;
Lee et al., 2009). A secondary analysis of the CALGB 30105 trial
(induction and concurrent chemotherapy with 74Gy RT) found
that, of the cases of RTOG grade 3–5 toxicity, 80% of patients had
N3 disease or aV20>38 (Salama et al., 2011). Graham et al. report
that the grade 2+ pneumonitis risk is 0% when the V20 is <22,
7% if the V20 is 22–31, 13% if the V20 is 32–40 and 36% if the
V20 is >40%. It is recommended that the V20 should be ≤37%
and the MLD ≤20Gy to reduce the risk of radiation pneumonitis
(Graham et al., 1999).
FUTURE DIRECTIONS
PROTON THERAPY
While most radiotherapy patients are treated with photon-based
3D-CRT or intensity-modulated radiotherapy, there has been an
increase in the number of and the access to proton treatment
facilities in the past decade. When treating any body site, dose
to critical structures can be minimized by capitalizing on the
Bragg Peak effect of proton beam therapy. This becomes especially
important when tumor volumes are located in close proximity
to radiosensitive structures such as normal lung, esophagus, and
spinal cord. Several single institution studies have evaluated dose-
volume histograms for treatment of NSCLC with either photon
or proton therapy. Chang et al. compared proton to photon treat-
ment plans for patientswith stages I and IIINSCLC. For 10patients
with stage I NSCLC, the mean lung dose, V5, V10, and V20 were
9.7Gy, 31.8, 24.6, and 15.8%, respectively, for 3D-CRT photon
therapy with prescribed dose of 66, 5.4 Gy, 13, 11.7, and 9.8%,
respectively, for photon therapy with a prescribed dose of 66 CGE
(p = 0.002), and 7.3Gy, 13.4, 12.3, and 10.9% for photon therapy
with a prescribed dose of 87.5 CGE (p = 0.002). Similar patterns
were seen for stage III patients treated with photon therapy to
63Gy when compared to proton therapy prescribed to 63 CGE
and 74 CGE (Chang et al., 2006). IMRT planning was used in
select cases, and the dose to critical structures in the photon IMRT
plan still exceeded that of the proton treatment plans. Zhang et al.
expanded on the utility of IMRT by comparing dose-volume his-
tograms for IMRT to intensity-modulated proton therapy (IMPT)
treatment plans for patients with stage IIIB NSCLC. IMPT plan-
ning allowed for increased sparing of the lung, heart, esophagus,
and spinal cord (Zhang et al., 2010).While proton therapy appears
superior in these dosimetric comparisons, the clinical value of
proton treatment is still unknown.
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Widesott et al. (2008) reviewed the published literature on pro-
ton therapy for NSCLC and concluded that, because of the small
number of institutions and studies addressing proton therapy for
NSCLC, there is currently insufﬁcient evidence to support the
routine use of proton therapy over photon therapy.
FUNCTIONAL IMAGE AND BIOMARKER-GUIDED TREATMENT
While it is outside of the scope of this review to discuss, in detail,
the emerging technologies and drug development research which
are inﬂuencing treatment of unresectable NSCLC, it is important
to mention these important advances. As previously discussed,
use of FDG-PET CT imaging has allowed for improved diagnostic
accuracy and treatment planning for NSCLC. In addition, nuclear
medicine studies such as FDG-PET and functional magnetic res-
onance imaging and spectroscopy have been utilized to obtain
biologic, functional, and metabolic characteristics of tumors. Ling
et al. have proposed the idea of creating a “biological target vol-
ume” (BTV) in addition to the normal radiotherapy treatment
planning structures. TheBTVwould encompass information from
these functional studies and allow for targeting of dose escalated
treatment toward regions of highly active tumor (Ling et al., 2000).
In addition to functional targeting, vast amounts of effort
are being directed at identifying molecular targets and creating
molecular therapies for cancer treatment. ERCC1 expression,
mutation of the tyrosine kinase domain of the epidermal growth
factor receptor, and inhibition of the PI3K pathway have lead to
increased radiosensitivity in cell lines (Das et al., 2010). Several
investigators have attempted create predictive models of radia-
tion sensitivity by identifying a set of genes involved in radiation
response (Torres-Roca et al., 2005;Amundson et al., 2008; Eschrich
et al., 2009). In the future, it is possible that these predictors of
radiosensitivity will allow for tailoring of radiation treatment dose
to individual patients.
CONCLUSION
Dose escalation in NSCLC remains a viable avenue of investi-
gation. The contribution of systemic agents, radiotherapy dose,
and patient selection make statements regarding the beneﬁt of
dose escalation challenging. As the aggressiveness of chemo-RT
increase, toxicity increases, and patient selection undoubtedly
leads to the improvements reported inPhase II clinical trials.While
the interim analysis of RTOG 0617 appears to show no survival
beneﬁt to dose escalated RT to 74Gy, investigators continue to
try to improve on the low survival rates of patients with Stage III
NSCLC. Unresectable and inoperable Stage III NSCLC continues
to provide a challenge for radiation oncologists andmedical oncol-
ogists worldwide. Dose escalation, in some settings has proven to
be associated with an overall survival beneﬁt, while in other trials,
there has been no beneﬁt to dose escalation. This reviewwas aimed
at summarizing the chemo-RT data which guide current practice.
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